Rainbow Coral Corp. executive leadership will preview the latest innovations and network with top biotechnology investors this week at Biotech Showcase 2015 in San Francisco, where the company’s joint venture partner, Nano3D Biosciences (n3D) will exhibit the revolutionary Bio-Assembler device.
About MEMS Accelerometers: MEMS accelerometers measure the translational or angular acceleration of sensor electronic devices. They consume less power and provide compact and robust sensing applications for electronic devices. They are often integrated with other MEMS sensors to provide accurate multi-axis sensing data.
A simple method to sense DNA, as well as potential biomarker proteins of cancer or other diseases such as Alzheimer's, may soon be within reach - thanks to the work of a team of Yokohama National University researchers in Japan.
Electroporation is a powerful technique in molecular biology. By using an electrical pulse to create a temporary nanopore in a cell membrane, researchers can deliver chemicals, drugs, and DNA directly into a single cell.
Nanoparticle drugs--tiny containers packed with medicine and with the potential to be shipped straight to tumors--were thought to be a possible silver bullet against cancer. However new cancer drugs based on nanoparticles have not improved overall survival rates for cancer patients very much. Scientists at the University of North Carolina at Chapel Hill now think that failure may have less to do with the drugs and tumors than it does the tumor's immediate surroundings.
Researchers from the Oak Ridge National Laboratory (ORNL) of the US Department of Energy are studying how the characteristics of water molecules on metal oxide surfaces can be used for controlling these minerals and using them for manufacturing products such as sound vehicle glass in frost and fog, highly efficient semiconductors for solar cells and organic light emitting diodes, and eco-friendly chemical sensors for industrial applications.
Researchers at the University of Copenhagen have developed a new type of superconducting ‘nanowire’ crystal that holds great promise for future semiconducting electronics. These crystals, on the atomic scale, fuse metallic and semiconducting materials.
By Stuart Milne
14 Jan 2015
A team of researchers from the Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California, Berkeley have collaborated to develop an accurate method using pre-designed molecular building blocks for synthesizing graphene nanoribbons. The nanoribbons built using this process have position-dependent, tunable bandgaps and other enhanced properties that hold promise for advanced electronic circuitry.
ICFO scientists along with other researchers have proved that boron nitride/graphene material system can hold strongly confined light and suppress Plasmon losses. Since the time graphene was discovered, it has become highly realistic to trap light in small circuits and control its flow electrically. This has been achieved by exploiting plasmons in which light and electrons move together as a single coherent wave.
Researchers at the Paul Scherrer Institute (PSI) have succeeded in switching tiny, magnetic structures using laser light and tracking the change over time. In the process, a nanometre-sized area bizarrely reminiscent of the Batman logo appeared. The research results could render data storage on hard drives faster, more compact and more efficient.
An ultra-thin nanomaterial is at the heart of a major breakthrough by Waterloo scientists who are in a global race to invent a cheaper, lighter and more powerful rechargeable battery for electric vehicles.
Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, today announced the presentation of new preclinical data on its Dicer substrate short interfering RNA (DsiRNA) therapeutics targeting MYC and â-catenin (CTNNB1) oncogenes in models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC).
Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the publication of Phase 2 data evaluating CPX-351 in adult patients with first-relapse acute myeloid leukemia (AML) in Cancer, a peer-reviewed journal of the American Cancer Society.
Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that over 80 patients randomized in the ongoing TRIBECA™ (TRIal establishing bioequivalence [BE] between Cynviloq™ and Albumin-bound paclitaxel*) registrational trial have been dosed. Sorrento intends to continue enrolling all qualified patients in the current screening process and anticipates having the "last patient in" by the end of January.
Researchers at Rensselaer Polytechnic Institute and Cornell University have devised a new nanoscale surface which uses an electrochemical anodization process in order to prevent the surface attachment of bacteria.
By Alexander Chilton
12 Jan 2015